Rilzabrutinib (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
300 | IgG4関連疾患 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04520451 (ClinicalTrials.gov) | August 21, 2020 | 11/8/2020 | Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | IgG4-Related Disease | Drug: rilzabrutinib;Drug: Glucocorticoids | Principia Biopharma Inc. | Massachusetts General Hospital | Recruiting | 18 Years | N/A | All | 25 | Phase 2 | United States |